Please enable JavaScript to continue using this application.

Compare $RLAY vs $VCYT | Chartloom

Compare

$RLAY vs $VCYT

Relay Therapeutics Inc · Veracyte Inc

RLAY

Relay Therapeutics Inc

VCYT

Veracyte Inc

Compare $RLAY vs $VCYT

Comparing Relay Therapeutics Inc and Veracyte Inc

RLAYRelay Therapeutics Inc

VCYTVeracyte Inc

RLAYRelay Therapeutics Inc

Market cap

$3.85B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

610.65x

Rev growth (TTM)

23.9%

YTD performance

118.6%

52W performance

192.6%

FCF yield

-5.5%

VCYTVeracyte Inc

Market cap

$3.61B

P/E (TTM)

32.42x

Forward P/E (NTM)

24.66x

Forward P/S (NTM)

5.69x

Rev growth (TTM)

17.3%

YTD performance

6.7%

52W performance

28.9%

FCF yield

4.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RLAY

VCYT

Detailed metrics comparison

RLAY

Relay Therapeutics Inc

VCYT

Veracyte Inc

Market Cap

RLAY$3.85B

VCYT$3.61B

Enterprise Value

RLAY$3.73B

VCYT$3.31B

Price

RLAY$17.88

VCYT$45.23

P/E Ratio

RLAYN/A

VCYT32.42x

P/S Ratio

RLAY372.39x

VCYT6.42x

EV/Sales

RLAY360.68x

VCYT5.89x

EV/EBITDA

RLAY0.00x

VCYT24.67x

P/B Ratio

RLAY4.67x

VCYT2.65x

P/FCF Ratio

RLAYN/A

VCYT21.74x

EV/FCF

RLAY-17.59x

VCYT19.94x

PEG Ratio

RLAYN/A

VCYT0.10x

Forward P/E (NTM)

RLAYN/A

VCYT24.66x

Forward P/S (NTM)

RLAY610.65x

VCYT5.69x

Revenue (TTM)

RLAY$10M

VCYT$562M

Revenue Growth (YoY)

RLAY23.9%

VCYT17.3%

Forward Rev Growth

RLAY64.1%

VCYT11.4%

Gross Margin (TTM)

RLAY0.0%

VCYT71.7%

Operating Margin (TTM)

RLAY0.0%

VCYT19.6%

EBITDA Margin (TTM)

RLAY-2978.0%

VCYT22.5%

Net Margin (TTM)

RLAY-2763.6%

VCYT20.4%

FCF Margin (TTM)

RLAY-2050.3%

VCYT29.5%

Net Income (TTM)

RLAY$-286M

VCYT$114M

FCF (TTM)

RLAY$-212M

VCYT$166M

EPS (TTM)

RLAY-$1.41

VCYT$1.40

ROE (TTM)

RLAY-4227.0%

VCYT8.6%

ROA (TTM)

RLAY-3867.0%

VCYT8.0%

ROIC (TTM)

RLAY-4227.0%

VCYT8.6%

Cash

RLAY$121M

VCYT$300M

Debt

RLAY$0

VCYT$0

Net Cash/Debt

RLAY$121M

VCYT$300M

Current Ratio (TTM)

RLAY18.27x

VCYT9.16x

Quick Ratio (TTM)

RLAY18.10x

VCYT8.60x

Debt/Equity (TTM)

RLAY0.00x

VCYT0.00x

Debt/Assets (TTM)

RLAY0.0%

VCYT0.0%

Interest Coverage (TTM)

RLAYN/A

VCYTN/A

Net Debt/EBITDA (TTM)

RLAY0.00x

VCYT0.00x

Beta

RLAY1.71

VCYT2.00

52W Performance

RLAY192.6%

VCYT28.9%

YTD Performance

RLAY118.6%

VCYT6.7%

% from 52W High

RLAY-15.9%

VCYT-25.7%

% from 52W Low

RLAY205.6%

VCYT53.6%

Asset Turnover (TTM)

RLAY0.01x

VCYT0.39x

FCF Yield (TTM)

RLAY-5.5%

VCYT4.6%

Earnings Yield (TTM)

RLAY-7.4%

VCYT3.2%

Dividend Yield (TTM)

RLAYN/A

VCYTN/A

Rule of 40

RLAY-2,026.4

VCYT46.8

EV/GP/RG

RLAYN/A

VCYT0.60

Ticker research

View RLAY research View VCYT research

Metric	RLAY Relay Therapeutics Inc	VCYT Veracyte Inc
Market & Valuation
Market Cap	$3.85B	$3.61B
Enterprise Value	$3.73B	$3.31B
Price	$17.88	$45.23
P/E Ratio	N/A	32.42x
P/S Ratio	372.39x	6.42x
EV/Sales	360.68x	5.89x
EV/EBITDA	0.00x	24.67x
P/B Ratio	4.67x	2.65x
P/FCF Ratio	N/A	21.74x
EV/FCF	-17.59x	19.94x
PEG Ratio	N/A	0.10x
Forward P/E (NTM)	N/A	24.66x
Forward P/S (NTM)	610.65x	5.69x
Revenue & Growth
Revenue (TTM)	$10M	$562M
Revenue Growth (YoY)	23.9%	17.3%
Forward Rev Growth	64.1%	11.4%
Profitability
Gross Margin (TTM)	0.0%	71.7%
Operating Margin (TTM)	0.0%	19.6%
EBITDA Margin (TTM)	-2978.0%	22.5%
Net Margin (TTM)	-2763.6%	20.4%
FCF Margin (TTM)	-2050.3%	29.5%
Net Income (TTM)	$-286M	$114M
FCF (TTM)	$-212M	$166M
EPS (TTM)	-$1.41	$1.40
ROE (TTM)	-4227.0%	8.6%
ROA (TTM)	-3867.0%	8.0%
ROIC (TTM)	-4227.0%	8.6%
Financial Health
Cash	$121M	$300M
Debt	$0	$0
Net Cash/Debt	$121M	$300M
Current Ratio (TTM)	18.27x	9.16x
Quick Ratio (TTM)	18.10x	8.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.71	2.00
52W Performance	192.6%	28.9%
YTD Performance	118.6%	6.7%
% from 52W High	-15.9%	-25.7%
% from 52W Low	205.6%	53.6%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.39x
FCF Yield (TTM)	-5.5%	4.6%
Earnings Yield (TTM)	-7.4%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,026.4	46.8
EV/GP/RG	N/A	0.60
Ticker research	View RLAY research	View VCYT research

Valuation

P/E Ratio

VCYT

32.42x

P/S Ratio

VCYT

6.42x

RLAY

372.39x

EV/FCF

RLAY

-17.59x

VCYT

19.94x

Growth & revenue

Revenue Growth TTM

RLAY

23.9%

VCYT

17.3%

Forward Revenue Growth

RLAY

64.1%

VCYT

11.4%

Profitability & performance

Gross Margin

VCYT

71.7%

RLAY

0.0%

ROE

VCYT

8.6%

RLAY

-4227.0%

FCF Yield %

VCYT

4.6%

RLAY

-5.5%

52-Week Performance

RLAY

192.6%

VCYT

28.9%

Detailed metrics comparison

RLAY

Relay Therapeutics Inc

VCYT

Veracyte Inc

Market Cap

RLAY$3.85B

VCYT$3.61B

Enterprise Value

RLAY$3.73B

VCYT$3.31B

Price

RLAY$17.88

VCYT$45.23

P/E Ratio

RLAYN/A

VCYT32.42x

P/S Ratio

RLAY372.39x

VCYT6.42x

EV/Sales

RLAY360.68x

VCYT5.89x

EV/EBITDA

RLAY0.00x

VCYT24.67x

P/B Ratio

RLAY4.67x

VCYT2.65x

P/FCF Ratio

RLAYN/A

VCYT21.74x

EV/FCF

RLAY-17.59x

VCYT19.94x

PEG Ratio

RLAYN/A

VCYT0.10x

Forward P/E (NTM)

RLAYN/A

VCYT24.66x

Forward P/S (NTM)

RLAY610.65x

VCYT5.69x

Revenue (TTM)

RLAY$10M

VCYT$562M

Revenue Growth (YoY)

RLAY23.9%

VCYT17.3%

Forward Rev Growth

RLAY64.1%

VCYT11.4%

Gross Margin (TTM)

RLAY0.0%

VCYT71.7%

Operating Margin (TTM)

RLAY0.0%

VCYT19.6%

EBITDA Margin (TTM)

RLAY-2978.0%

VCYT22.5%

Net Margin (TTM)

RLAY-2763.6%

VCYT20.4%

FCF Margin (TTM)

RLAY-2050.3%

VCYT29.5%

Net Income (TTM)

RLAY$-286M

VCYT$114M

FCF (TTM)

RLAY$-212M

VCYT$166M

EPS (TTM)

RLAY-$1.41

VCYT$1.40

ROE (TTM)

RLAY-4227.0%

VCYT8.6%

ROA (TTM)

RLAY-3867.0%

VCYT8.0%

ROIC (TTM)

RLAY-4227.0%

VCYT8.6%

Cash

RLAY$121M

VCYT$300M

Debt

RLAY$0

VCYT$0

Net Cash/Debt

RLAY$121M

VCYT$300M

Current Ratio (TTM)

RLAY18.27x

VCYT9.16x

Quick Ratio (TTM)

RLAY18.10x

VCYT8.60x

Debt/Equity (TTM)

RLAY0.00x

VCYT0.00x

Debt/Assets (TTM)

RLAY0.0%

VCYT0.0%

Interest Coverage (TTM)

RLAYN/A

VCYTN/A

Net Debt/EBITDA (TTM)

RLAY0.00x

VCYT0.00x

Beta

RLAY1.71

VCYT2.00

52W Performance

RLAY192.6%

VCYT28.9%

YTD Performance

RLAY118.6%

VCYT6.7%

% from 52W High

RLAY-15.9%

VCYT-25.7%

% from 52W Low

RLAY205.6%

VCYT53.6%

Asset Turnover (TTM)

RLAY0.01x

VCYT0.39x

FCF Yield (TTM)

RLAY-5.5%

VCYT4.6%

Earnings Yield (TTM)

RLAY-7.4%

VCYT3.2%

Dividend Yield (TTM)

RLAYN/A

VCYTN/A

Rule of 40

RLAY-2,026.4

VCYT46.8

EV/GP/RG

RLAYN/A

VCYT0.60

Ticker research

View RLAY research View VCYT research

Metric	RLAY Relay Therapeutics Inc	VCYT Veracyte Inc
Market & Valuation
Market Cap	$3.85B	$3.61B
Enterprise Value	$3.73B	$3.31B
Price	$17.88	$45.23
P/E Ratio	N/A	32.42x
P/S Ratio	372.39x	6.42x
EV/Sales	360.68x	5.89x
EV/EBITDA	0.00x	24.67x
P/B Ratio	4.67x	2.65x
P/FCF Ratio	N/A	21.74x
EV/FCF	-17.59x	19.94x
PEG Ratio	N/A	0.10x
Forward P/E (NTM)	N/A	24.66x
Forward P/S (NTM)	610.65x	5.69x
Revenue & Growth
Revenue (TTM)	$10M	$562M
Revenue Growth (YoY)	23.9%	17.3%
Forward Rev Growth	64.1%	11.4%
Profitability
Gross Margin (TTM)	0.0%	71.7%
Operating Margin (TTM)	0.0%	19.6%
EBITDA Margin (TTM)	-2978.0%	22.5%
Net Margin (TTM)	-2763.6%	20.4%
FCF Margin (TTM)	-2050.3%	29.5%
Net Income (TTM)	$-286M	$114M
FCF (TTM)	$-212M	$166M
EPS (TTM)	-$1.41	$1.40
ROE (TTM)	-4227.0%	8.6%
ROA (TTM)	-3867.0%	8.0%
ROIC (TTM)	-4227.0%	8.6%
Financial Health
Cash	$121M	$300M
Debt	$0	$0
Net Cash/Debt	$121M	$300M
Current Ratio (TTM)	18.27x	9.16x
Quick Ratio (TTM)	18.10x	8.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.71	2.00
52W Performance	192.6%	28.9%
YTD Performance	118.6%	6.7%
% from 52W High	-15.9%	-25.7%
% from 52W Low	205.6%	53.6%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.39x
FCF Yield (TTM)	-5.5%	4.6%
Earnings Yield (TTM)	-7.4%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,026.4	46.8
EV/GP/RG	N/A	0.60
Ticker research	View RLAY research	View VCYT research